These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29507566)

  • 1. Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.
    Mackiewicz-Wysocka M; Czerwińska P; Filas V; Bogajewska E; Kubicka A; Przybyła A; Dondajewska E; Kolenda T; Marszałek A; Mackiewicz A
    Postepy Dermatol Alergol; 2017 Oct; 34(5):490-498. PubMed ID: 29507566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF
    McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
    Elife; 2021 Nov; 10():. PubMed ID: 34812139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct senescence mechanisms restrain progression of dysplastic nevi.
    Lorbeer FK; Rieser G; Goel A; Wang M; Oh A; Yeh I; Bastian BC; Hockemeyer D
    PNAS Nexus; 2024 Feb; 3(2):pgae041. PubMed ID: 38371417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct senescence mechanisms restrain progression of dysplastic nevi.
    Lorbeer FK; Rieser G; Goel A; Wang M; Oh A; Yeh I; Bastian BC; Hockemeyer D
    bioRxiv; 2023 Jul; ():. PubMed ID: 37503286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
    Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
    PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
    Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
    J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
    Yeh I; von Deimling A; Bastian BC
    J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
    Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report.
    Lam K; Gates GA; Bach DQ; Cheng K
    Case Rep Dermatol; 2024; 16(1):133-139. PubMed ID: 38831934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
    Kiszner G; Wichmann B; Nemeth IB; Varga E; Meggyeshazi N; Teleki I; Balla P; Maros ME; Penksza K; Krenacs T
    Virchows Arch; 2014 May; 464(5):603-12. PubMed ID: 24682564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.